BETTER CELLS FOR BETTER THERAPIES Trademark

Trademark Overview

On Friday, January 8, 2016, a trademark application was filed for BETTER CELLS FOR BETTER THERAPIES with the United States Patent and Trademark Office. The USPTO has given the BETTER CELLS FOR BETTER THERAPIES trademark a serial number of 86870139. The federal status of this trademark filing is REGISTERED as of Tuesday, February 18, 2020. This trademark is owned by Fate Therapeutics, Inc.. The BETTER CELLS FOR BETTER THERAPIES trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:

Reagents for research, drug discovery and development, and clinical laboratory use

Pharmaceutical preparations and therapeutic agents to modulate cell function or cell fate; reagents for clinical medical and medical use; pharmaceutical preparations and therapeutic agents for the treatment of cancer and immune disorders; pharmaceutical and therapeutic agents for use as immunotherapies
better cells for better therapies

General Information

Serial Number86870139
Word MarkBETTER CELLS FOR BETTER THERAPIES
Filing DateFriday, January 8, 2016
Status700 - REGISTERED
Status DateTuesday, February 18, 2020
Registration Number5991391
Registration DateTuesday, February 18, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 15, 2016

Trademark Statements

Goods and ServicesReagents for research, drug discovery and development, and clinical laboratory use
Goods and ServicesPharmaceutical preparations and therapeutic agents to modulate cell function or cell fate; reagents for clinical medical and medical use; pharmaceutical preparations and therapeutic agents for the treatment of cancer and immune disorders; pharmaceutical and therapeutic agents for use as immunotherapies

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, September 29, 2016
Primary Code001
First Use Anywhere DateTuesday, January 7, 2020
First Use In Commerce DateTuesday, January 7, 2020
International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 15, 2016
Primary Code005
First Use Anywhere DateSaturday, August 24, 2019
First Use In Commerce DateSaturday, August 24, 2019

Trademark Owner History

Party NameFate Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameFate Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameFate Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Tuesday, February 18, 2020REGISTERED-PRINCIPAL REGISTER
Friday, January 17, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, January 16, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, January 16, 2020STATEMENT OF USE PROCESSING COMPLETE
Friday, January 10, 2020USE AMENDMENT FILED
Friday, January 10, 2020TEAS STATEMENT OF USE RECEIVED
Saturday, July 20, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 19, 2019EXTENSION 5 GRANTED
Monday, July 8, 2019EXTENSION 5 FILED
Monday, July 8, 2019TEAS EXTENSION RECEIVED
Wednesday, January 9, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 7, 2019EXTENSION 4 GRANTED
Monday, January 7, 2019EXTENSION 4 FILED
Monday, January 7, 2019TEAS EXTENSION RECEIVED
Tuesday, July 31, 2018CORRECTED NOA E-MAILED
Tuesday, July 31, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 30, 2018EXTENSION 3 GRANTED
Tuesday, July 10, 2018EXTENSION 3 FILED
Monday, July 30, 2018DIVISIONAL PROCESSING COMPLETE
Tuesday, July 10, 2018DIVISIONAL REQUEST RECEIVED
Monday, July 30, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 10, 2018TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, July 10, 2018TEAS EXTENSION RECEIVED
Friday, January 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 10, 2018EXTENSION 2 GRANTED
Wednesday, January 10, 2018EXTENSION 2 FILED
Wednesday, January 10, 2018TEAS EXTENSION RECEIVED
Wednesday, June 14, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 12, 2017EXTENSION 1 GRANTED
Monday, June 12, 2017EXTENSION 1 FILED
Monday, June 12, 2017TEAS EXTENSION RECEIVED
Tuesday, January 10, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 15, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 15, 2016PUBLISHED FOR OPPOSITION
Wednesday, October 26, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 3, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 29, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 28, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 28, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 26, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 26, 2016NON-FINAL ACTION E-MAILED
Tuesday, April 26, 2016NON-FINAL ACTION WRITTEN
Monday, April 25, 2016ASSIGNED TO EXAMINER
Friday, January 15, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, January 12, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

better therapies cells therapeutic pharmaceutical agents cell medical reagents preparations clinical immunotherapies treatment